Chemiluminescence immunoassay technology, a core segment in the in vitro diagnostic (IVD) field, has achieved technological breakthroughs and market expansion amid the wave of domestic substitution in recent years. Chinese enterprises, leveraging advantages in detection sensitivity, throughput efficiency, and cost control, have gradually broken the monopoly of international giants. Their products are widely used in cancer screening, infectious disease diagnosis, endocrine testing, and other scenarios. Below are the top 10 manufacturers with leading market performance in 2025
1.Hangzhou Realy Tech Co., Ltd.
Each year we participate in medical shows in various countries such as Medlab, Medica and AACC etc. We have got CE certificates, ISO 13485 quality system certification, Manufacture License, Marketing Authorization in the country of origin. We are also preparing FDA and more other certificates. Real Tech' s sales network has covered more than 80 countries and areas, providing an exciting opportunity for distribution of quality products at a very competitive price. We are dedicated to making the world a better place by providing people with high quality products and services.
2.Mindray Medical
A leading enterprise with a dominant domestic market share, its chemiluminescence systems cover all scenarios from primary care to top-tier hospitals. The equipment is renowned for high stability and intelligence, supporting integration with biochemical-immune assembly lines. Its test menu includes over 200 items such as tumor markers and thyroid function, with overseas installations growing by over 30% annually.
3.Autobio Diagnostics
Focused on magnetic particle chemiluminescence technology, it holds 208 product registration certificates, with infectious disease and tumor detection items accounting for over 70%. It performed prominently in national bulk purchasing; its preoperative eight-item testing products have become the first choice for medical institutions due to high specificity, covering 70% of tertiary hospitals.
4.Snibe Medical
Developer of the world's first 1,000-test/hour model MAGLUMI X10. It boasts strong overseas performance, with 2,281 new installations in the first half of 2024, where medium and large-sized equipment accounted for 64.8%. Its market share continues to rise in Europe and Southeast Asia.
5.YHLO Biotech
It broke the monopoly of acridinium ester direct luminescence technology, with autoimmune and reproductive health testing as its specialties. The equipment supports modular cascading, reaching a maximum speed of 2,400 tests/hour. It is the first domestic IVD enterprise to enter the Japanese market, with 12 co-registered testing items accelerating its global expansion.
6.Maccura Biotechnology
A representative of comprehensive IVD industrial chain layout, its chemiluminescence products synergize with biochemical and molecular diagnostics. The C8+X8 combination supports flexible expansion, covering both routine and specialty test items. In 2024, the number of reagents certified by the EU CE increased to over 150.
7.Permed Biomedical
A leader in electrochemiluminescence technology, its eCL8000/9000 series, with a 9-minute first-result speed, is suitable for emergency scenarios. Its products are exported to over 30 countries, with installations exceeding 1,000 units in two years, excelling in diabetes and cardiac marker testing.
8.Tellgen Corporation
Focused on combined tumor marker testing, its multi-index synchronous detection system reduces sample usage by 50%. Core products hold both NMPA and CE certifications, widely adopted by China's Top 100 hospitals in early screening for lung and colorectal cancers.
9.Kehua Bio-Engineering
It excels in infectious disease testing, with reagents for hepatitis B and C achieving internationally leading sensitivity. The equipment is suitable for primary laboratories, supporting automatic lotion preparation. In 2025, its newly added HIV testing reagents passed WHO prequalification.
10.Bohui Innovation
Deeply engaged in maternal and child health, its luminescence systems cover specialty items such as neonatal screening and vitamin testing. Its preoperative eight-item testing ranked third in Jilin's bulk purchasing, with over 60% of installations in primary medical institutions.